propafenone / Generic mfg. - LARVOL DELTA

Atrial fibrillation : An overview of the various treatment options (PubMed, Herz) - "Electrical cardioversion is particularly suitable for the acute treatment of hemodynamically unstable patients, while pharmacological treatment and catheter ablation represent long-term treatment approaches. Class IC antiarrhythmic drugs such as flecainide and propafenone are contraindicated in patients with structural heart disease."

Journal • Atrial Fibrillation • Cardiovascular • Heart Failure • Ischemic stroke

Is Intravenous Lipid Emulsion Therapy Effective in Propafenone Intoxication? (PubMed, Klin Padiatr) - No abstract available

Journal

Dronedarone vs class Ic agents for early AF: Protocol for the DRIVE-AF randomized clinical trial. (PubMed, Heart Rhythm O2) - P4 | "Participants will be randomized (1:1) to receive either dronedarone (400 mg twice daily) or standard-of-care class Ic agents (flecainide or propafenone) for 12 months. By establishing comparative efficacy and safety, this study aims to refine international standards for pharmacologic rhythm control in early AF. ClinicalTrials.gov identifier: NCT07270848."

Clinical • Journal • Atrial Fibrillation • Cardiovascular

Beyond pooled analysis: sex-specific cardiovascular adverse event reporting signals with antiarrhythmic drugs in FAERS. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Sex-stratified analysis uncovered "hidden" associations undetected in pooled data, including propafenone-QT prolongation in men and amiodarone-QT prolongation in women. Adverse event profiles were often drug-specific and opposing: cardiogenic shock showed higher reporting odds among males for sotalol, whereas flecainide showed higher reporting odds in females...Sex-specific CV-AE profiles reporting patterns are often masked in pooled analyses, underscoring the need for sex-stratified pharmacovigilance to guide personalized antiarrhythmic therapy. The identified associations should be considered hypothesis-generating and require validation in datasets with richer clinical information."

Adverse events • Journal • Retrospective data • Cardiovascular

Brugada Syndrome or Drug-Induced Phenocopy? Diagnostic Challenges in a Patient with Paroxysmal Atrial Fibrillation Treated with Propafenone (AHA 2026) - "Abstract is embargoed at this time."

Clinical • Atrial Fibrillation • Cardiovascular • Genetic Disorders

A Case of Propafenone and Warfarin Toxicity Precipitated by Nirmatrelvir/Ritonavir for COVID-19 (AHA 2026) - "Abstract is embargoed at this time."

Clinical • Infectious Disease • Novel Coronavirus Disease

Compound heterozygous TECRL variants in an adolescent: Early electrocardiographic abnormalities and sudden cardiac arrest. (PubMed, HeartRhythm Case Rep) - No abstract available

Journal • Cardiovascular

Cryo-InitialAF: Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation (clinicaltrials.gov) - P=N/A | N=320 | Completed | Sponsor: Ruijin Hospital | Recruiting ➔ Completed | Trial completion date: Jan 2026 ➔ Aug 2025

Trial completion • Trial completion date • Atrial Fibrillation • Cardiovascular

Case Report: Overlap of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia in two Chinese children with CALM2-related calmodulinopathy. (PubMed, Front Pediatr) - "She remained event-free on propranolol and propafenone for two years...Despite treatment with propranolol plus mexiletine, syncopal episodes continued, with the QTc interval further prolonged to 0.62 s...Patients who experience recurrent syncope coexisting with significant sinus bradycardia may have more severe phenotypes with higher risk of malignant arrhythmias, warranting earlier or more aggressive evaluation for device therapy. Genetic testing is recommended for suspected pediatric channelopathies with phenotype-guided individualized treatment."

Journal • Cardiovascular • Gene Therapies • Pediatrics • Ventricular Tachycardia • CALM2

Safety of Flecainide and Propafenone in Patients With Atrial Fibrillation and Structural Heart Disease. (PubMed, J Cardiovasc Electrophysiol) - "Across structural heart disease populations, including a well-powered CAD subgroup, class Ic antiarrhythmic therapy for AF was not associated with excess ventricular arrhythmia risk, and no subgroup demonstrated harm. The absence of a proarrhythmic signal across diverse study designs and substrates provides supportive, though not definitive, hypothesis-generating evidence regarding the safety of these agents in carefully selected patients with stable disease and preserved ventricular function. Prospective randomized trials are needed to confirm these findings. PROSPERO Registration: CRD420261411804."

Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Myocardial Infarction

A meta-analysis of randomized controlled trials on atenolol's impact on postoperative atrial fibrillation in adults undergoing cardiac surgery. (PubMed, Medicine (Baltimore)) - "Atenolol did not demonstrate superiority over sotalol in reducing POAF (RR, 2.39; 95% CI: 1.41-4.04; P = .001) with moderate heterogeneity (I2 = 40%; P = .19). Furthermore, no significant difference was observed between atenolol and the control group (comprising propafenone, metoprolol, nebivolol, and digoxin) in the prevention of POAF (RR, 1.28; 95% CI: 0.76-2.16; P = .35) with moderate heterogeneity (I2 = 43%; P = .15). Recent studies suggest that atenolol could be a safe and effective intervention for the prevention of POAF in adult patients undergoing CS."

Clinical • Journal • Retrospective data • Atrial Fibrillation • Cardiovascular

Atypical Andersen-Tawil Syndrome in an Asymptomatic Child With Bidirectional Ventricular Tachycardia and Incipient Tachycardiomyopathy. (PubMed, JACC Case Rep) - "Bidirectional ventricular tachycardia is a distinct ECG pattern that should raise suspicion of Andersen-Tawil syndrome and warrants genetic evaluation with cascade family screening. In this patient, the combination of propafenone and beta-blocker therapy was associated with suppression of bidirectional ventricular tachycardia, significant reduction in ventricular arrhythmic load, and reversal of tachycardiomyopathy, suggesting a potential therapeutic alternative when flecainide is not available."

Journal • Cardiomyopathy • Cardiovascular • Heart Failure • Pediatrics • Ventricular Tachycardia

Rhythm vs. rate control for treatment of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis of randomized controlled trials. (PubMed, Front Cardiovasc Med) - "An aggressive rhythm control strategy (ibutilide, procainamide, propafenone, or electric cardioversion) was associated with higher odds of in-hospital conversion to sinus rhythm [OR: 4.01 (95% CI: 1.30, 12.39)] and a higher risk of medication-related adverse events (hypotension, bradycardia, and syncope) [RR: 3.05 (95% CI: 1.05, 8.89)]. Among postcardiac surgery patients with new-onset atrial fibrillation, there was no evidence that a rhythm control treatment strategy resulted in better outcomes than a rate control strategy. https://www.crd.york.ac.uk/PROSPERO/view/CRD42019128559, identifier CRD42019128559."

Journal • Retrospective data • Review • Atrial Fibrillation • Cardiovascular • Hypotension

Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone. (PubMed, Diabetes Obes Metab) - "Initiation of amiodarone in patients receiving sulfonylureas was associated with a higher risk of hypoglycemia compared with other antiarrhythmics. Given the continued use of sulfonylureas in diabetes care, this finding highlights the need for caution and close monitoring during their concomitant use with amiodarone."

Journal • Cardiovascular • Diabetes • Hypoglycemia • Metabolic Disorders • Severe Hypoglycemia • Type 2 Diabetes Mellitus

Pediatric premature atrial contractions: Clinical characteristics, diagnosis, and management-A literature review. (PubMed, Am Heart J Plus) - "Clinically, frequent or non-conducted PACs may cause "pseudo-bradycardia," occasionally requiring pharmacological intervention with agents such as propafenone...PACs are predominantly benign in children with structurally normal heartsyet comprehensive evaluation is mandated for patients with symptomatic frequent PACs concurrent structural heart disease or significant electrocardiographic abnormalities. Management should be guided by age-specific reference limits and the underlying cardiac substrate."

Journal • Review • Cardiomyopathy • Cardiovascular • Heart Failure • Pediatrics

Role of antazoline in cardioversion of atrial fibrillation: A PRISMA-compliant systematic review and meta-analysis. (PubMed, Medicine (Baltimore)) - "Antazoline might be more effective than propafenone and amiodarone in achieving sinus rhythm in AF, with no significant differences in safety outcomes."

Clinical • Journal • Retrospective data • Review • Atrial Fibrillation • Cardiovascular • Hypotension

Three Empty Bottles and a Wide QRS: Rapid Alkalinization Rescue in Propafenone Overdose. (PubMed, J Innov Card Rhythm Manag) - "This case highlights the electrophysiologic manifestations of propafenone toxicity and underscores the value of QRS duration as a dynamic marker of toxicity severity and treatment response. Early alkalinization with intravenous sodium bicarbonate may rapidly correct conduction disturbances and stabilize malignant arrhythmias in severe class IC anti-arrhythmic overdose."

Journal • Acute Kidney Injury • Cardiovascular • Critical care • Metabolic Disorders • Nephrology • Renal Disease • Ventricular Tachycardia

Effectiveness and safety of Guipi Mixture for the treatment of premature ventricular contractions (heart-spleen deficiency syndrome): study protocol for a randomized, double-blind, placebo-controlled, multicentre trial. (PubMed, Front Cardiovasc Med) - "Current Western guidelines recommend pharmacotherapy or catheter ablation, with conservative drug therapy (e.g., lidocaine, propafenone, metoprolol, amiodarone, verapamil) remaining the mainstay. Metoprolol tartrate, a first-line drug, is effective for PVCs but has single targets, limited efficacy, and potential long-term cardiovascular adverse effects...This study will provide evidence on the efficacy and safety of Guipi Mixture for PVCs (heart-spleen deficiency syndrome) and explore its impact on patients' quality of life. http://itmctr.ccebtcm.org.cn/, identifier ITMCTR2025001333."

Clinical • Journal • Cardiomyopathy • Cardiovascular

Treatment of supraventricular arrhythmias in critical care patients with sepsis. (PubMed, Front Cardiovasc Med) - "The Propafenone vs. Amiodarone for Supraventricular Arrhythmias in Septic Shock trial, the only double-blind randomized comparison of these agents, showed similar 24-hour cardioversion rates but faster cardioversion and fewer recurrences with propafenone, with treatment effects strongly modified by left atrial volume index. Trials of ultra-short acting beta-blockers demonstrated reliable heart-rate control but heterogeneous and fragile mortality signals, with the suggested benefit largely driven by single-center esmolol data and not consistently reproduced in multicenter landiolol studies. Evidence for digoxin and magnesium supports primarily adjunctive roles rather than first-line rate- or rhythm-control strategies. No study has evaluated vernakalant specifically in sepsis, limiting the evidence for its use in hemodynamically unstable patients...Overall, current evidence supports prioritizing correction of triggers and individualized selection of a rate- vs...."

Journal • Review • Acute Respiratory Distress Syndrome • Atrial Fibrillation • Cardiovascular • Critical care • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • Septic Shock

A simple, high-throughput LC-MS/MS method for the simultaneous quantification of four antiarrhythmic drugs and two metabolites: large-scale application to 622 patient samples. (PubMed, Talanta) - "Here, we developed and validated a simple, high-throughput liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of four commonly prescribed AADs-amiodarone, dronedarone, flecainide, and propafenone-and two metabolites, noramiodarone and debutyldronedarone, in human serum, and applied it to routine clinical samples. AAD concentrations showed substantial inter-individual variability at identical daily doses, and high proportions of samples were below the therapeutic ranges, supporting the potential utility of routine AAD TDM. This LC-MS/MS method provides a rapid, robust, and clinically practical platform for routine individualized AAD TDM in real-world serum samples with complex matrices."

Journal • Cardiovascular • Psychiatry

The present and future of antiarrhythmic drugs. (PubMed, JRSM Cardiovasc Dis) - "Flecainide, propafenone, and dronedarone have demonstrated their reliable efficacy and safety, even in patients with structural heart disease, which should allow clinicians to reduce their reliance on amiodarone. Previous concerns regarding the proarrhythmic risk of dofetilide and ibutilide are currently managed through careful patient selection and adequate QT interval monitoring. Novel targeted AADs are advancing through the development pipeline, of which etripamil and landiolol have already been approved. Other emerging drugs, such as SK channel blockers (AP30663 and AP31969), RyR2 blockers, CaMKII inhibitors, and TASK-1 blockers (doxapram), are aligned with the new paradigm of atrial fibrillation that focuses on triggers and re-entry...Developing concepts such as atrial cardiomyopathy allows clinicians to characterize substrate objectively, in order to assess disease severity and individualize antiarrhythmic treatment. The future of antiarrhythmic therapy will be..."

Journal • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Heart Failure

Propafenone is associated with fewer recurrences of supraventricular arrhythmias in mechanically ventilated patients with septic shock and right ventricular dysfunction. (PubMed, Front Cardiovasc Med) - P4 | "These findings are hypothesis-generating and suggest that propafenone may represent a promising alternative to amiodarone for rhythm control in critically ill patients with right ventricular dysfunction, warranting further prospective evaluation. ClinicalTrials.gov Identifier: NCT03029169."

Journal • Atrial Fibrillation • Cardiovascular • Heart Failure • Septic Shock

Propafenone Toxicity Presenting With Wide QRS and Transient Ventricular Dyskinesia. (PubMed, JACC Case Rep) - "Toxicity in new wide-QRS rhythm on class Ic drugs should be assumed. QRS narrowing after bicarbonate is key. Early treatment prevents fatal complications."

Journal • Cardiovascular • Heart Failure • Movement Disorders • Pulmonary Disease

Polypharmacy, drug related nitrosocontamination and the link to lichen planus/subsequent development of keratinocyte and mucosal cancer/oral leukoplakia: presentation of a case and update on the new pathogenetic vision (EADV-Sp 2026) - "Introduction The association between drug-induced lichen planus - whether oral/mucosal or solely cutaneous - involves a diverse range of drugs, including ACE inhibitors, diuretics, and beta blockers, as well as quinidine, NSAIDs, hydroxychloroquine, antiretroviral medications for HIV, penicillamine, TNF inhibitors, and certain medications for type 2 diabetes...Results We present for the first time in the medical literature, a case of a 91-year-old patient with a 2-year history of oral lichen planus and subsequent oral leukoplakia (Fig.1a-c) following 2-year beta-blocker (bisoprolol) and/or anti-arrhythmic (propafenone) administration, with no history of smoking and alcohol consumption, and discuss the possible role of nitrosamines as a cofactor in the malignant transformation of ulcerative lichenoid lesions to oral leukoplakia/mucosal carcinoma...The segment is demarcated by an abundant lichenoid round-cell stroma, prominent among collagen fibers throughout the tunica..."

Clinical • Dermatology • Dermatopathology • Diabetes • Human Immunodeficiency Virus • Infectious Disease • Lichen Planus • Metabolic Disorders • Oncology • Oral Cancer • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Type 2 Diabetes Mellitus

(N-nitroso) Propafenone induced advanced nodular melanoma and the potential pathogenetic relationship to nitroso photo carcinogenesis (EADV-Sp 2026) - "Once again, we present a patient who took the antiarrhythmic (nitroso-) drug propafenone and developed a relatively short-term nodular melanoma with a subsequent fatal outcome. We comment on the role of drug-mediated nitrosogenesis and its relationship to Nitroso -photocarcinogenesis and onco-pharmacogenesis."

Metastases • Genetic Disorders • Melanoma • Oncology • Skin Cancer • Solid Tumor • RAS